These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 38202262)

  • 1. The Clinical Analysis of Checkpoint Inhibitor Pneumonitis with Different Severities in Lung Cancer Patients: A Retrospective Study.
    Huang H; Chen R; Xu Y; Fang N; Shao C; Xu K; Wang M
    J Clin Med; 2024 Jan; 13(1):. PubMed ID: 38202262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bronchoalveolar lavage fluid analysis in patients with checkpoint inhibitor pneumonitis.
    Chen R; Shi Y; Fang N; Shao C; Huang H; Pan R; Xu Y; Wang M; Liu X; Xu K; Zhu R; Wang M
    Cancer Immunol Immunother; 2024 Sep; 73(11):235. PubMed ID: 39271538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical features and prognostic analysis of checkpoint inhibitor pneumonitis in patients with non-small cell lung cancer].
    Chen RX; Liu XN; Xu Y; Shi YJ; Wang MQ; Shao C; Huang H; Xu K; Wang MZ; Xu ZJ
    Zhonghua Jie He He Hu Xi Za Zhi; 2024 Mar; 47(3):207-213. PubMed ID: 38448169
    [No Abstract]   [Full Text] [Related]  

  • 4. Safety and efficacy of immunotherapy rechallenge following checkpoint inhibitor-related pneumonitis in advanced lung cancer patients: a retrospective multi-center cohort study.
    Lin X; Deng H; Chu T; Chen L; Yang Y; Qiu G; Xie X; Qin Y; Liu M; Xie Z; Ouyang M; Li S; Song Y; Petrella F; Jakopovic M; Tsoukalas N; Solli P; Goto T; Saito Y; Zhou C
    Transl Lung Cancer Res; 2022 Nov; 11(11):2289-2305. PubMed ID: 36519018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radiographic features and prognosis of early- and late-onset non-small cell lung cancer immune checkpoint inhibitor-related pneumonitis.
    Huang A; Xu Y; Zang X; Wu C; Gao J; Sun X; Xie M; Ma X; Deng H; Song J; Ren F; Pang L; Qian J; Yu Z; Wan S; Chen Y; Pan L; Zhuang G; Liu S; Xue X
    BMC Cancer; 2021 May; 21(1):634. PubMed ID: 34051746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk Factors for Immune Checkpoint Inhibitor-Related Pneumonitis in Cancer Patients: A Systemic Review and Meta-Analysis.
    Zhou P; Zhao X; Wang G
    Respiration; 2022; 101(11):1035-1050. PubMed ID: 36108598
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical outcomes and risk factor of immune checkpoint inhibitors-related pneumonitis in non-small cell lung cancer patients with chronic obstructive pulmonary disease.
    Zeng Z; Qu J; Yao Y; Xu F; Lu S; Zhang P; Yao Y; Li N; Zhou J; Wang Y
    BMC Pulm Med; 2022 Dec; 22(1):458. PubMed ID: 36456932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytomegalovirus infection as an underestimated trigger for checkpoint inhibitor-related pneumonitis in lung cancer: a retrospective study.
    Lin X; Lu T; Li S; Xie X; Chen X; Jiang J; Qin Y; Xie Z; Liu M; Ouyang M; Zhong N; Song Y; Zhou C
    Clin Transl Oncol; 2021 Feb; 23(2):389-396. PubMed ID: 32613413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High mortality and poor treatment efficacy of immune checkpoint inhibitors in patients with severe grade checkpoint inhibitor pneumonitis in non-small cell lung cancer.
    Tone M; Izumo T; Awano N; Kuse N; Inomata M; Jo T; Yoshimura H; Minami J; Takada K; Miyamoto S; Kunitoh H
    Thorac Cancer; 2019 Oct; 10(10):2006-2012. PubMed ID: 31482678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rate and risk factors of recurrent immune checkpoint inhibitor-related pneumonitis in patients with lung cancer.
    Tao H; Li F; Wu D; Ji S; Liu Q; Wang L; Liu B; Facchinetti F; Leong TL; Passiglia F; Hu Y
    Transl Lung Cancer Res; 2022 Mar; 11(3):381-392. PubMed ID: 35399572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dynamic changes in the radiologic manifestation of a recurrent checkpoint inhibitor related pneumonitis in a non-small cell lung cancer patient: A case report.
    Tan PX; Huang W; Liu PP; Pan Y; Cui YH
    World J Clin Cases; 2021 Oct; 9(30):9108-9113. PubMed ID: 34786393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pneumonitis in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Immunotherapy: Incidence and Risk Factors.
    Suresh K; Voong KR; Shankar B; Forde PM; Ettinger DS; Marrone KA; Kelly RJ; Hann CL; Levy B; Feliciano JL; Brahmer JR; Feller-Kopman D; Lerner AD; Lee H; Yarmus L; D'Alessio F; Hales RK; Lin CT; Psoter KJ; Danoff SK; Naidoo J
    J Thorac Oncol; 2018 Dec; 13(12):1930-1939. PubMed ID: 30267842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of pneumonitis risk between immunotherapy alone and in combination with chemotherapy: an observational, retrospective pharmacovigilance study.
    Li H; Zheng Y; Xu P; Li Z; Kuang Y; Feng X; He J; Li J; Chen X; Bai L; Tang KJ
    Front Pharmacol; 2023; 14():1142016. PubMed ID: 37124234
    [No Abstract]   [Full Text] [Related]  

  • 14. The association between the incidence risk of pneumonitis and PD-1/PD-L1 inhibitors in advanced NSCLC: A meta-analysis of randomized controlled trials.
    Lin GF; Xu Y; Lin H; Yang DY; Chen L; Huang LL; Su XS; Xu YX; Zeng YM
    Int Immunopharmacol; 2021 Oct; 99():108011. PubMed ID: 34426108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management, risk factors and prognostic impact of checkpoint-inhibitor pneumonitis (CIP) in lung cancer - A multicenter observational analysis.
    Frost N; Unger K; Blum TG; Misch D; Kurz S; Lüders H; Olive E; Raspe M; Hilbrandt M; Koch M; Böhmer D; Senger C; Witzenrath M; Grohé C; Bauer T; Modest DP; Kollmeier J
    Lung Cancer; 2023 May; 179():107184. PubMed ID: 37040677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peripheral Blood Biomarkers for Early Diagnosis, Severity, and Prognosis of Checkpoint Inhibitor-Related Pneumonitis in Patients With Lung Cancer.
    Lin X; Deng H; Yang Y; Wu J; Qiu G; Li S; Xie X; Liu M; Xie Z; Qin Y; Song Y; Zhou C
    Front Oncol; 2021; 11():698832. PubMed ID: 34327140
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk factors for immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer.
    Chao Y; Zhou J; Hsu S; Ding N; Li J; Zhang Y; Xu X; Tang X; Wei T; Zhu Z; Chu Q; Neal JW; Wu JT; Song Y; Hu J
    Transl Lung Cancer Res; 2022 Feb; 11(2):295-306. PubMed ID: 35280322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive factors and prognosis of immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer patients.
    Liu X; Hao N; Yang S; Li J; Wang L
    Front Oncol; 2023; 13():1145143. PubMed ID: 37182127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of Pneumonitis Rates and Severity in Patients With Lung Cancer Treated by Immunotherapy, Radiotherapy, and Immunoradiotherapy.
    Aiad M; Fresco K; Prenatt Z; Tahir A; Ramos-Feliciano K; Stoltzfus J; Harmouch F; Wilson M
    Cureus; 2022 Jun; 14(6):e25665. PubMed ID: 35677739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of baseline peripheral-blood eosinophil count with immune checkpoint inhibitor-related pneumonitis and clinical outcomes in patients with non-small cell lung cancer receiving immune checkpoint inhibitors.
    Chu X; Zhao J; Zhou J; Zhou F; Jiang T; Jiang S; Sun X; You X; Wu F; Ren S; Zhou C; Su C
    Lung Cancer; 2020 Dec; 150():76-82. PubMed ID: 33080551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.